NS-2028 NLT 98%

NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC₅₀ values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity^[1]. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC₅₀ values of 17 nM and 20 nM^[1]. NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC₅₀ of 30 nM^[1]. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM)^[1]. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability^[2]. IC50 & Target: IC50: 30 nM (soluble Guanylyl Cyclase sGC)^[1] In Vitro: NS-2028 (10 μM; 24 hours) inhibits 25% cell number in comparation with those grown in the presence of vehicle^[2].
NS-2028 (10 μM; 30 mins) attenuates VEGF-induced EC migration by inhibiting p38 MAPK activation^[2]. In Vivo: NS-2028 (Deliver orally; 1 g/L; 8 days) exhibits a significant reduction of new vessel formation in the avascular rabbit cornea in response to VEGF pellet implants^[2].